Baloncibart Phase 2 Signal in POTS

Company Regeneron Event Type Randomized Phase 2 results (PINNACLE) Modality Monoclonal antibody Asset Baloncibart (REGN7544) Target NPR1 Disease Area Postural orthostatic tachycardia syndrome Summary Regeneron disclosed randomized Phase 2 PINNACLE results for NPR1-blocking baloncibart in postural orthostatic tachycardia syndrome. The 450 mg dose lowered the…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *